Join our community of smart investors

AstraZeneca – positive results with a logistical advantage

The UK pharma heavyweight has delivered positive clinical results for its Covid-19, complete with a significant advantage from a logistical perspective
AstraZeneca – positive results with a logistical advantage
  • Positive phase three clinical trial results - combined efficacy of 70 per cent
  • storage and transportation of the vaccine can be conducted at normal refrigerated conditions
IC TIP: Buy at 8179p

AstraZeneca (AZN), in conjunction with the University of Oxford, has released positive clinical trial results of its Covid-19 vaccine within days of Pfizer (NYSE: PFE) and BioNTech announcing that they were filing for emergency vaccine authorisation from the US Food and Drug Administration for their candidate.

To continue reading...
OR
Register for free
Read 3 articles for free each month
* Excl. premium articles
Have an account? Sign in